Denmark to pass verdict on Lundbeck's migraine drug

When Danish Medicines Agency sits for its November meeting, today, its agenda will include a submission to authorize Vyepti, Lundbeck’s migraine drug, as a standard treatment.

Photo: Thomas Borberg/Politiken/Ritzau Scanpix

Today, Wednesday, Lundbeck waits in anticipation on news from the company’s home country of Denmark.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs